Get latest articles and stories on Business at LatestLY. Bangalore (Karnataka) [India], May 21: A first-of-its-kind clinical trial in India shows remarkable results for people with diabetes. The trial was conducted using BugSpeaks, a flagship technology of Leucine Rich Bio, India's first microbiome-based company. BugSpeaks is a gut microbiome profiling test that provides nutritional recommendations based on the individual's gut microbiota profile. With India being called the diabetes capital of the world housing more than 101 million people with diabetes, the results of this study are groundbreaking for the prevention and management of diabetes. Business News | Gut Microbiota Diets Boost Effectiveness of Anti-Diabetic Medications, Study Finds.